Comparing Clinical and Economic Outcomes of Biologic and Conventional Medications in Postmenopausal Women with Osteoporosis

摘要

Rationale, aims and objectivesBiologics are substantially more expensive than their conventional counterparts but it is unclear whether extra costs deliver better health outcomes. We compare clinical and economic outcomes between teriparatide (monthly cost ~1120) and bisphosphonates (monthly costs ~14) among postmenopausal women with osteoporosis.